Brcaone 100mg Tablet

Brcaone 100mg tablet is a an anti-cancer medication. This treatment approach treats ovarian and breast cancer by blocking the PARP enzyme which is the primary cause of cancer formation in the body. Its active ingredient is Olaparib that contains PARP enzyme which prevent cancer cells from multiplying and help stop the spread of cancer in the body. The dose and duration must be prescribed by the healthcare professional, as it is not recommended to the adults under the age of 18. Strict adherence to the prescribed regimen is essential to ensure the effectiveness of the treatment.

Breast cancer and ovarian cancer

Brcaone 100mg tablet cause various side effects like any other medication, do not self administer on any of the doses. It is better to consult with the doctor if any of these symptoms persist:
● Muscle cramps
● Confusion, visual disturbances, seizures, and headache
● Breathlessness
● Swelling of feet
● Changes in heartbeat
● High blood pressure
● Pneumonia
● Loss of appetite
● Sensitivity, tingling and burning sensation of the skin
● Nausea, vomiting, and diarrhea
● Mouth ulcers
● Constipation

Brcaone 100mg tablet is used under doctor prescription. Most of the healthcare professionals prescribed the tablet with or without the food at the fixed time everyday to enhance the effectiveness of the treatment. Do not skip or stop the medication without the consultation of a healthcare provider. Always follow the prescribed dosage and schedule carefully to ensure the best result and reduce the side effects of the treatment.

Breast and ovarian cancer is formed by the mutation in genetic such as BRC1 and BRC2, which normally help regulate cell growth repair damaged DNA. These genetic mutations disrupt normal cell function, leading to uncontrolled cell growth and tumor formation. Brcaone 100mg tablet is a targeted therapy contains PARP inhibitor enzyme which directly attacks on the cancer cell growth and stop the formation of tumor size in the body. The medicine also improves the immune function through that body can fight off the other diseases as well.

• Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., ... & Matulonis, U. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine, 366(15), 1382-1392.
• Forster, M. D., Dedes, K. J., Sandhu, S., Frentzas, S., Kristeleit, R., Ashworth, A., ... & Molife, L. R. (2011). Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nature reviews Clinical oncology, 8(5), 302-306.
• Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., ... & Kindler, H. L. (2019). Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. New England Journal of Medicine, 381(4), 317-327.
• Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H., Sonke, G. S., ... & Friedlander, M. (2015). Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. The lancet oncology, 16(1), 87-97.
• Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., ... & Saad, F. (2022). Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM evidence, 1(9), EVIDoa2200043.